NMD Pharma A/S | LinkedIn
Thomas H. Pedersen - CEO at NMD Pharma | The Org
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
PDF) Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial
Thomas Holm Pedersen - Crunchbase Person Profile
Thomas Holm Pedersen - Crunchbase Person Profile
PDF) Development and evaluation of liposomal formulation containing nimodipine on anxiolytic activity in mice
HITTA ER ET A UN AMI TA ON HI HA UT ME AT THE
PDF) Influence of acid‐base dissociation equilibria during electromembrane extraction
Agenda - Neurotech Partnering
Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
Cancers | Free Full-Text | The Identification of RNA-Binding Proteins Functionally Associated with Tumor Progression in Gastrointestinal Cancer | HTML
Novo A/S Novo Seeds. Letter from the CEO SYNLAB. Novo Ventures - PDF Free Download
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
Thomas H. Pedersen - CEO at NMD Pharma | The Org
Annual Report 2019 by Lundbeckfonden - issuu
NMD Pharma
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
PDF) The Impact of Oligofructose on Stimulation of Gut Hormones, Appetite Regulation and Adiposity
aging • The Journal of Frailty & Aging
NMD Pharma
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
